www.thelifesciencesreport.com Review:



The Life Sciences Report - Biotech and Life Sciences stock coverage from experts- learn to invest in biotech and life sciences stocks - Insight, analysis and ideas about life sciences investments from the best experts in the biotech and life sciences industry

  • http://www.thelifesciencesreport.com/pub/htdocs/exclusive.html Streetwise Interviews - The Gold Report — Read what analysts and experts are saying about the gold sector.
  • http://www.thelifesciencesreport.com/pub/dir/13 The Life Sciences Report - The Alliance for Regenerative Medicine (ARM)'s mission is to advance regenerative medicine by representing, supporting and engaging all stakeholders in the field, including companies, academic research institutions, patient advocacy groups, foundations, health insurers, financial institutions and other organizations.Based in Washington, D.C., ARM is a global advocacy organization that promotes legislative, regulatory, reimbursement, investment, technical and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understanding of the field and its potential to transform human healthcare. “ For the past several years, The Life Sciences Report (TLSR) has served as a major proponent of the Alliance for Regenerative Medicine (ARM) and our members. Their unique formula for reaching investors, both institutional and retail, via in-depth interviews, has helped educate the investor community and propel growth in the regenerative medicine sector. We feel TLSR's commitment to quality content is a constant consideration in everything they do, and their combination of information and insight is a unique feature not found anywhere else. We value our continued partnership with TLSR, proudly support their activities and greatly appreciate their on-going endorsement of ARM and our members. ” —Alliance for Regenerative Medicine
  • http://www.thelifesciencesreport.com/pub/dir/14 The Life Sciences Report - Neurotechnology Industry Organization is a global trade association representing companies involved in neuroscience (drugs, software, device, diagnostics), brain research institutes and patient advocacy groups.
  • http://www.thelifesciencesreport.com/pub/na/exploring-solutions-to-healthcares-spending-crisis Exploring Solutions to Healthcares Spending Crisis - Rising healthcare costs continue to preoccupy providers, patients, politicians and investors. Some cost increases stem from inefficiencies in the medical system, some from social and demographic trends, and others are a function of profit motives on the part of insurers and a few drug companies. In this article for The Life Sciences Report, Dr. Len Yaffe of Stoc*Doc Partners reviews the issues and proposes some cures.
  • http://www.thelifesciencesreport.com/pub/na/analysts-keep-focus-on-durects-dur-928 Analysts Keep Focus on DURECTs DUR-928 - The FDA's recent Complete Response Letter for Remoxy, which is licensed by DURECT to Pain Therapeutics, has not changed the view of several analysts who follow DURECT. They are focused on DUR-928 for NASH and impaired kidney function, indications that are of great interest to Big Pharma.
  • http://www.thelifesciencesreport.com/pub/na/viveves-treatment-for-improving-womens-sexual-function-may-leapfrog-the-competition Viveves Treatment for Improving Womens Sexual Function May Leapfrog the Competition [VIVE] - Private-pay aesthetic procedures constitute a trend in medical devices, according to Anthony Vendetti, Director of Research at Maxim Group. These nonreimbursable types of procedures have seen rapid growth in the past decade. In this interview with The Life Sciences Report, Vendetti discusses Viveve Medical, which is attempting to leapfrog the competition to get FDA approval to use its patented radiofrequency technology to improve women's sexual function.
  • http://www.thelifesciencesreport.com/pub/na/stock-moving-catalysts-anticipated-for-regeneus-in-q4-16 Stock-Moving Catalysts Anticipated for Regeneus in Q4/16 [RGS] - Australian regenerative medicine company Regeneus Ltd. has a handful of stock-moving Q4/16 catalysts on the calendar, among them a potential licensing agreement for its mesenchymal stem cell technology in Japan.
  • http://www.thelifesciencesreport.com/pub/na/imagin-a-better-way-to-detect-bladder-cancer Imagin, a Better Way to Detect Bladder Cancer - Bob Moriarty profiles Imagin Medical, a company that has developed a new way of detecting bladder cancer through endoscopes.
  • http://www.thelifesciencesreport.com/pub/na/regeneus-secures-government-funding-for-r-d Regeneus Secures Government Funding for R&D [RGS] - The Australian government has bolstered Regeneus, a regenerative medicine company targeting cancer, osteoarthritis and other musculoskeletal conditions, with $2.73 million in funding.
  • http://www.thelifesciencesreport.com/pub/na/three-shots-on-goal-in-q4-16-for-durect-corp Three Shots on Goal in Q4/16 for DURECT Corp. [DRRX] - With a trifecta of share-moving milestones anticipated in Q4/16, including possible FDA approval of abuse-resistant opioid Remoxy, Laidlaw & Co. Analyst Jim Molloy sees blue sky ahead for DURECT Corp.
  • http://www.thelifesciencesreport.com/pub/co/6484 Actinium Pharmaceuticals Inc. ATNM:NYSE.MKT - Discover expert commentary on Actinium Pharmaceuticals Inc. ATNM:NYSE.MKT. A snapshot of the company you cannot get anywhere else
  • http://www.thelifesciencesreport.com/pub/co/4634 Resverlogix Corp. RVX:TSX - Resverlogix Corp. is developing RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor for the potential treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease and chronic kidney disease.
  • http://www.thelifesciencesreport.com/pub/co/7294 Viveve Medical Inc. VIVE:NASDAQ - Discover expert commentary on Viveve Medical Inc. VIVE:NASDAQ. A snapshot of the company you cannot get anywhere else
  • http://www.thelifesciencesreport.com/pub/co/4735 Sunesis Pharmaceuticals Inc. SNSS:NASDAQ - Sunesis Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers.
  • http://www.thelifesciencesreport.com/pub/co/4503 DURECT Corp. DRRX:NASDAQ - Discover expert commentary on DURECT Corp. DRRX:NASDAQ. A snapshot of the company you cannot get anywhere else

    Country:, North America, US

    City: -84.636 Michigan, United States

  • hoping for a fun voyage - This product is super expensive for what you get

    Are you kidding? There isn't enough liquid drops in here to last more than 2 weeks!!! How in the world can I expect to see results in that short of time? This product is super expensive for what you get. I can't believe people have rated this product good or very good!!! You have to have enough of the product for several months not 2 weeks to see if it actually works.

  • Deidra Toney - Wouldn't Recommend It

    I have tried this for several weeks now. I cannot get a close shave on my legs - always leaves stubble. And I see no different in the amount of time it takes the hair to grow back. I wouldn't waste my money on this product, if I were you. They might perfect this someday, but not today.

  • An excellent introduction to Massive Attack - An excellent introduction to Massive Attack

    The opening track "Safe From Harm" is stunning. I couldn't stop playing it when I first bought the album. This album is great for it's beats, lyric references, and all of the different vocals. The weak track is "Hymn of the Big Wheel". It goes on a little too long, but the rest of the album kicks - "Unfinished Sympathy", "Blue Lines" and "Daydreaming" are the other standouts. This album may not be as dark as "Mezzanine" but that doesn't matter. The groundwork that these guys laid starting with this album makes it essential.